-
FDA Approves Expanded Botox (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity
drugs
August 02, 2021
Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion of Botox® to include eight new muscles for the treatment of upper limb spasticity in adults.
-
FDA Approves Expanded Use for BOTOX
contractpharma
July 13, 2020
For the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy.
-
FDA Accepts sBLA for BOTOX for Neurogenic Detrusor Overactivity
americanpharmaceuticalreview
July 02, 2020
Allergan, an AbbVie company, announced the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental biologics license application (sBLA) to expand the BOTOX® prescribing information for the treatment of signs and ...
-
Botox gets license update in UK
pharmatimes
March 27, 2020
Allergan has received a license update for Botox (botulinum toxin type A) in the UK, clarifying that appropriately trained and qualified healthcare professionals.
-
FDA approves Allergan’s BOTOX for upper limb spasticity
pharmaceutical-technology
June 26, 2019
The US Food and Drug Administration has approved Allergan’s supplemental biologics application (sBLA) for its BOTOX treatment for paediatric patients with upper limb spasticity.
-
FDA Approves Botox (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
drugs
June 24, 2019
FDA Approves Botox (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity.
-
“All-powerful Drug” of Allergan: Botox Pushed Clinical Trial, MDD Clinical Protocol Postponed
PharmaSources/Zhulikou431
January 09, 2019
Phase III clinical trial of Allergan’s Botox for major depressive disorder (MDD) will be pushed to the second half of 2019 (H2 2019), said the spokesperson of the company recently.
-
Botox May Help Prevent Post-Op A-Fib
drugs
December 06, 2018
Botox has other uses beyond enhancing lips and minimizing facial wrinkles. Scientists now say it may help prevent atrial fibrillation after heart surgery......
-
Allergan defuses Botox threat with $195M Bonti buy
fiercebiotech
September 18, 2018
Bonti’s EB-001 works similarly to Botox, but it acts more quickly and its effects don’t last as long.
-
Botox, fillers steal the show as Allergan posts Q2 beats
fiercepharma
August 07, 2017
Allergan’s catching a break this year, and it’s one that Thursday allowed it to hike its guidance for 2017.